Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for July 2009
July 1, 2009
- Human Genome Sciences to Host July 20 Conference Call to Discuss Top-Line Phase 3 Results for Benlysta (Formerly Lymphostat-B in Systemic Lupus Erythematosus
- Pharming Confirms Positive Results From Fina l Analysis Of Rhucin Studies
- New Review on Prostvac Published by Key Investigators From NCI
- Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa
- Study Showed Vyvanse (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment
- Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM211, a Novel Product Candidate for the Treatment of Respiratory Diseases
July 2, 2009
- Sucampo Reports Top-Line Results of Phase 2 Clinical Trial of Cobiprostone for Prevention of NSAID-Induced Gastrointestinal Injuries
- Lu AA24530 shows positive results in major depressive disorder phase II study
- Sepracor Provides Update on Clinical Trials for SEP-225289 and LUNESTA Pediatrics
- iCo Therapeutics Publishes Review of Diabetic Retinopathy Treatment
- Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
July 6, 2009
- 5-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus Compared to NPH
- Aeolus Pharmaceuticals' AEOL 10150 Significantly Increases Survival in Mice Exposed to Radiation when Administered After Exposure
- New Online Resource Launches For Patients With Chronic Myeloid Leukemia
July 7, 2009
- XOMA Announces Conference Call and Webcast On July 14 to Review Top Line Multi-dose and Other Results of Its Phase 1 Clinical Trial of XOMA 052 in Type 2 Diabetes
- Vical Announces News Release and Conference Call/Webcast Schedule to Present TransVax CMV Vaccine Phase 2 Interim Efficacy Results
- Published in The Lancet...Cervarix protects against the five most common cancer-causing virus types
- Presse Release: Further interim analyses confirm good clinical efficacy of the BT-061 monoclonal antibody.
- South Jersey Healthcare Selects MobileMD for Health Information Exchange Service
- Stinson Brand Innovation, Inc. Releases White Paper Trends In Pharma Branding Over The Next Five Years
- Denosumab Demonstrates Superiority Over Zometa in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases
- EnVivo to Share Results of its EVP-6124 Phase Ib/IIa Trial at The International Conference on Alzheimer's Disease
- Landmark Study for GSK's Cervical Cancer Vaccine Published in The Lancet
- AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
July 8, 2009
- ARYx Therapeutics Announces Results of Phase 2/3 Clinical Trial on Anticoagulant Agent Tecarfarin
- Livingston Securities ?Healthcare Investment Series? Webinar Covers Emerging Models for Pharma Exits and Deals
- Beacon Solutions Announces New Purchase Order from Fortune 500 Pharmaceutical Company
- BioCis Pharma Reports Positive Phase IIa Clinical Results in Atopic Dermatitis
- McKesson Provider Technologies Deploys Synygy Sales Performance Management Solution
- Digital Consumer Solutions Inc Launches DCSI Content Network
- Vical TransVax CMV Vaccine Achieves Promising Interim Clinical Results in Phase 2 Trial
July 9, 2009
- Revance Therapeutics Announces Efficacy of Topical Botulinum Toxin Type A for the Treatment of Facial Wrinkles
- Elan to Showcase Its Leadership in Alzheimer's Disease at Upcoming International Meeting
- Array BioPharma Announces Top-Line Results in Two Phase 1 Clinical Trials
- Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
- Data Published in The New England Journal of Medicine Support Use of Raxibacumab (ABthrax) for the Treatment of Inhalation Anthrax
- Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
- Questcor Launches New Corporate Website
- Physicians and Pharmacists Reach for OTC Relief With New Epocrates Reference
- Iontophoretic Drug Delivery System (IDDS) Containing Lidocaine and Epinephrine is Effective in Reducing Pain Associated With Insertion of an Intravenous Catheter in a Phase 2 Clinical Trial
July 13, 2009
- Elan and Transition Therapeutics Announce Phase 1 Data Showing ELND005 Achieves Desired Concentrations in Brain Tissue and Cerebrospinal Fluid
- New Data from Phase III SATURN Study Showed Tarceva Improved Overall Survival When Used Immediately After Initial Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
- CytRx's INNO-206 Demonstrates Statistically Significant Tumor Shrinkage in Animal Trial for Breast Cancer
July 14, 2009
- Maxygen Announces Positive Results of MAXY-G34 Phase IIa Study in Breast Cancer Patients
- Noven Reports Positive Phase 2 Results for Mesafem Non-Hormonal Therapy for Vasomotor Symptoms
- IP Advocate Enhances Interactive IPAO Forum with New ?Expert Opinions' Section
- Safety and Cognitive Stability Are Key Findings in Phase IIA Trial of New Alzheimer's Disease Treatment from Humanetics Corporation
- Light-directed drug delivery system slows growth of invasive tumours
- Oxford Biomedica Announces Update On Phase I/Ii Study Of Prosavin In Parkinson's Disease
- Avid Radiopharmaceuticals Phase II Results Featured in Two Presentations at Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD)
- New Podcast in Patient Perspectives Series: Searching for a Cure
- EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimer's Disease Transgenic Mouse Model With Gamma-Secretase Modulator
- Study Evaluating Efficacy and Safety of Two Low-dose Regimens of Premarin Vaginal Cream for the Treatment of Moderate to Severe Vaginal Atrophy Now Published
- Endocyte to Present Data on EC145 at the IASLC 13th World Conference on Lung Cancer
- ParagonRx Creates New Website Featuring REMS Help Center for Pharma
- Patient Enrollment Complete for Phase I/II Clinical Trial for GALNS for Morquio A Syndrome
- Analysis of Four Large Post-Marketing Surveillance Studies Describe Clinical Effects of Sucrose-Formulated Recombinant Factor VIII
July 15, 2009
- I-many Government Pricing Goes Live at Graceway Pharmaceuticals
- Targacept's TC-5214 Achieves All Primary and Secondary Outcome Measures in Phase 2b Trial as Augmentation Treatment for Major Depressive Disorder
- Abraxis BioScience Completes Enrollment of Pivotal Phase III Advanced Lung Cancer Study Evaluating ABRAXANE Vs. Taxol
- Oncolytics Biotech Inc. Research Collaborators Present Glioma Reovirus Research at ASV Annual Meeting
- Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing
- A Phase III Alzheimer's Drug Increases Levels of Beta Amyloid in the Brain - But Still Provides Benefits
- Results From Drug Trials and New Risk Factors Announced at International Alzheimer's Conference
- Pfizer Announces New Phase 1 Data From Two Novel Compounds For Alzheimer's Disease At ICAD Annual Meeting
- Sapient Delivers New Online Multilingual Resource to Support Thousands of Families Affected by Rare Congenital Syndrome
- ReachMD Announces a New Radio Programming Series, ?Diabetes Discourse,? hosted by Steven V. Edelman, MD
July 16, 2009
- National Survey Indicates Latinos and Blacks in America Twice as Likely as Caucasians to Be Diagnosed with Diabetes
- Results of Phase I and Phase IIa Clinical Studies Confirm the Inhibitory Effect of Proprietary Ipsen's BIM23A760 First-in-Class ?Chimeric? Compound on Growth Hormone, IGF-1 and Prolactin Levels1
- Inovio Biomedical H1N1 Influenza DNA Vaccines Demonstrate 100% Responses Against Swine Flu in Vaccinated Pigs
- avVaa World Health Care Products Inc. Announces Web Site Design for Neuroskin Psoriasis Relief DRTV Campaign
- Results of Phase I and Phase IIa clinical studies confirm the inhibitory effect of proprietary Ipsen?s BIM23A760 first-in-class ?chimeric? compound on growth hormone, IGF-1 and prolactin levels
- Targacept?s TC-5214 Achieves All Primary and Secondary Outcome Measures in Phase 2b Trial as Augmentation Treatment for Major Depressive Disorder
- Raptor Pharmaceuticals Corp. to Present at 2009 Cystinosis Research Network Family Conference
- XOMA Announces Positive Results From U.S. Phase 1 Trial of XOMA 052 in Type 2 Diabetes
- Oncolytics Biotech Inc. Announces Publication of Research on Synergistic Activity of Reovirus and Chemotherapy in NSCLC
- Former AMA Chief and Other Members of the Coalition to Protect Patients' Rights to Hold Press Conference to Discuss Health Reform
July 17, 2009
- Bionovo's Estrogen Receptor Beta Selective Drugs Have Unique Gene Expression and Cell Type Specificity
- BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
- PolyMedix to Present at 5th International AIDS Society (IAS) Conference
July 19, 2009
July 20, 2009
- Alnylam and Cubist Announce Complete Data from Phase II Study of ALN-RSV01 in Lung Transplant Patients Naturally Infected with Respiratory Syncytial Virus
- First Potential Lupus-Specific Treatment in Sight
- Debate Over Advertising Prescription Drugs to Consumers Goes Online at New ProCon.org Website
July 21, 2009
- Xeloda-Oxaliplatin Combination (XELOX) Shown to Be More Effective Than Standard Chemotherapy Regimen in Adjuvant Colon Cancer
- Isentress (raltegravir), from Merck, was as Effective as Efavirenz at Suppressing HIV Viral Load and Increasing CD4 Cell Counts in Treatment-Naïve Patients up to 144 Weeks When Used in Combination Therapy
- Exenatide Once Weekly Provided Superior Glucose Control Compared To Lantus in Head-to-Head DURATION-3 Study
- 96-Week MERIT ES Analysis Shows Efficacy Of Pfizer's HIV/AIDS Treatment Celsentri/Selzentry (Maraviroc) In Treatment-Naïve HIV Patients; Results Consistent With 48-Week Analysis
- Foresight Biotherapeutics Announces Positive Results from an Open Label Pilot Study in Patients with Viral Conjunctivitis
- Thermo Fisher Scientific Showcases Breadth of Clinical Chemistry Solutions at AACC 2009
- Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients
- Isentress (raltegravir), from MSD, was as Effective as Efavirenz at Suppressing HIV Viral Load and Increasing CD4 Cell Counts in Treatment-Naïve Patients up to 144 Weeks When Used in Combination Therapy
- Raltegravir as Effective as Efavirenz at Suppressing HIV Viral Load and Increasing CD4 Cell Counts in Treatment-Naive Patients Up to 144 Weeks When Used in Combination Therapy
- Orexigen Successfully Meets Phase 3 Endpoints in Obesity Trials
July 22, 2009
- Takeda and Sucampo Report Top-Line Results of Two Phase 3 Trials of Lubiprostone in Opioid-Induced Bowel Dysfunction
- -Contrave Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments-
- Actelion's PGI2 receptor agonist demonstrates efficacy in pulmonary arterial hypertension patients - Morbidity-Mortality Phase III study to be initiated before year-end
- The American Academy of Pharmaceutical Scientists (AAPS) Hires Environics Communications to Provide PR for Annual Meeting
- 96-Week Safety and Efficacy Findings Presented for Intelence (etravirine) As Part of HIV Combination Therapy
- AlphaVax Announces Results from Initial Testing of Its H1N1 (Swine) Influenza Vaccine
- BIO Issues Call for Sessions for 2010 BIO International Convention
- Data Show ATryn Effectively Prevents Serious Blood Clots in Patients with Hereditary Antithrombin Deficiency
- FoldRx Pharmaceuticals Announces Positive Results from Pivotal Phase II/III Clinical Study of Tafamidis
- Siemens Showcases Innovative Products and Educational Offerings
- Access Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
- Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration
- NCCN Will Convene National Policy Summit on Comparative Effectiveness in Cancer Care
- Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer
- Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2009 Financial Results on July 23, 2009
- PolyMedix to Present at 5th International AIDS Society (IAS) Conference Cape Town, South Africa
- New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine (TDF/FTC) Versus Boosted Protease Inhibitor Regimen of Atazanavir/Ritonavir Plus TDF/FTC Revealed
- SoCalBio's 11th Investor & Partnership Conference to Explore Post-Recession Funding Strategies for Life Science Firms
- New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies
- Merck Issues Statement on WHO Study Showing First Evidence That Elimination of River Blindness is Feasible in Africa
July 23, 2009
- Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi3 Clinical Trial of R788 in Rheumatoid Arthritis
- Landmark Five-Year African Study Indicates That HIV Therapy May Be Given Safely in Resource-Limited Settings Without Routine Laboratory Monitoring
- Millennium Laboratories Research Study Reveals Lower Opiate Cutoff Levels Identify Higher Percentage of Patients Taking Illegal Drugs
- Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for Benlysta in Systemic Lupus Erythematosus
- New FDLI Monograph on Federal Price Reporting Requirements Provides Essential Guidance on Commercial Strategy, Compliance Issues
July 24, 2009
- Orexo announces positive Phase III results for KW-2246 in Japan
- R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent
- Advancing Adaptive Design and Personalized Medicine in CNS Trials: Clinical, Regulatory and Statistical Viewpoints
- Chinese Scientist Fanyi Zeng to Present at World Stem Cell Summit on iPS Cells Producing Viable Mice
- ChemOutsourcing Unveils 2009 Attendee List for September Show in New Jersey
July 27, 2009
- ARIAD Announces Preliminary Results from Ongoing Clinical Trial of Its Investigational, Bcr-Abl Inhibitor ? AP24534 ? in Drug-Resistant Chronic Myeloid Leukemia
- Inovio Biomedical Universal Dengue DNA Vaccine Demonstrates Strong Immune Responses Against All Four Serotypes
July 28, 2009
- Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms
- Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression
- Quark Pharmaceuticals Announces Data Indicating Potential Utility of QPI-1007 for Treatment of Glaucoma
- Saphris (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia
- Suven Presented Positive Phase-I clinical data of SUVN-502 for Alzheimer's disease at ICAD 2009, Vienna, Austria
- NeurogesX Announces Preliminary Results of FDA-Requested Qutenza Study
- Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis
- Economy is Driving Many Osteoporotic Women to Retire Later - But Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease
- CytRx Drug Candidate INNO-206 Results in Ovarian Tumor Shrinkage in Animal Trials
- Ongoing Study Shows That Endovascular Therapy is Associated With High Cure Rate for Childhood Eye Cancer
- Biofrontera AG (DE) - Ad hoc: Clinical study with BF-derm1 shows efficacy in severe chronic urticaria
- Study Shows Cancer Vaccines Led to Long-Term Survival for Patients with Metastatic Melanoma and to Long Periods of Disease Control After Completion of Therapy
July 29, 2009
- DURECT to Present at the BMO Capital Markets Healthcare Conference
- ImmuneRegen BioSciences Confirms Homspera's Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration
- QuatRx Announces Further Positive Phase 3 Results For Ophena (Ospemifene Tablets) in Postmenopausal Vaginal Atrophy
- NanoBio to Announce Key Preclinical Data on Nanoemulsions for the Treatment of Acne at American Academy of Dermatology Summer Meeting
- Sciele Pharma and Plethora Solutions Announce Positive Results of Final Phase III Pivotal Trial for PSD502 for Premature Ejaculation
- Foundation for the National Institutes of Health Announces 2009 mHealth Summit
- Elagolix Successful in Six Month Lilac Petal Study; Safety and Efficacy Confirmed in Patients With Endometriosis
July 30, 2009
- Obagi Medical Products Releases Results of a Clinical Trial Showing Optimized Patient Outcomes When Condition & Enhance System is Used in Combination with Botulinum Toxin Type A
- Obagi Medical Products Reveals Results of a Meta-Analysis Comparing the Company's Novel 5 Percent Solubilized BPO to Other Prescription 5 Percent BPO and Combination BPO/Clindamycin Topical Products
- Stemline Therapeutics CEO to Present at IBC's New Frontiers in Cancer Drug Development Conference
- Child and Adolescent Psychiatry and Mental Health Publishes Vyvanse ADHD Data
- Cardinal Health Welcomes Record Number of Attendees at its Annual Independent Pharmacy Trade Show
- Teva's Forum Draws Key Pennsylvania Healthcare Leaders
- Medicago's H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose
July 31, 2009
- Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
- Clinical Trial by Licensee Does Not Meet Primary Endpoint
- Second Phase III Study Showed Lucentis Improved Vision in Patients With Retinal Vein Occlusion
- AVEO's Tivozanib Demonstrates Anti-Tumor Activity in Engineered Lung Tumors Exhibiting Treatment Resistant Mutations
- 17 Regional Companies Accepted During First-Round Vetting for the Inaugural Rocky Mountain Life Science Investor Conference, September 17th in Denver
- Obagi Medical Products' CLENZIderm M.D. Serum Gel Significantly Reduces Non-Inflammatory Lesions with Visible Results as Early as Week One
